NMN Supplementation for Menopausal Women

Two things decline sharply in your 40s and 50s, and only one of them gets talked about. Estrogen is the headliner, the hormone whose fall defines the menopausal transition and drives the symptoms women have come to expect: hot flashes, broken sleep, shifting moods, a body that suddenly seems to keep score differently. The quieter decline is cellular. NAD+ (nicotinamide adenine dinucleotide), a molecule every cell uses to turn food into usable energy and to repair damaged DNA, falls steadily across the same years. Menopause is not only a hormonal event. It is also a cellular energy event, and the two are more intertwined than most women have been told.

The age-related fall in NAD+ is not theoretical. Studies measuring NAD+ directly in human tissue, including skin biopsy data first reported by Massudi and colleagues, show substantial declines across adult life. ³ By the time a woman reaches her perimenopausal years, her cells are operating with measurably less of the molecule that powers their metabolic and repair machinery.

What makes this particularly relevant to menopause is the link between estrogen and a longevity enzyme called SIRT1, which is involved in cellular repair, stress response, and metabolic regulation. Based on preclinical and mechanistic evidence reviewed across sirtuin pathways, estrogen is proposed to support SIRT1 activity. ⁴ When estrogen falls, SIRT1 activity is proposed to follow. The cell loses one of its key repair coordinators at the same moment NAD+, the fuel SIRT1 depends on, is also dropping.

There is a baseline difference too. Emerging evidence on sex differences in NAD+ metabolism suggests women may start with lower baseline NAD+ than men, which means menopause may accelerate an already steeper downward trajectory. A notable NMN clinical trial used a male-only design, underscoring that female NAD+ biology warrants its own dedicated research. ⁵

Layered on all this is CD38, an enzyme that consumes NAD+. CD38 activity rises with the low-grade inflammation that accompanies midlife ageing, and may be further elevated by the hormonal shifts of menopause, meaning NAD+ is not only produced more slowly with age but also broken down more quickly.

The supplement industry tends to imply that any NAD+-related study applies equally to anyone over 40. The reality is narrower, and more interesting.

The only published, placebo-controlled randomised trial of NMN conducted specifically in postmenopausal women was carried out by Yoshino and colleagues and published in Science in 2021. ¹ It enrolled 25 postmenopausal women who had prediabetes and were overweight or obese. Thirteen women received 250mg of NMN daily for 10 weeks; twelve received placebo. The primary finding was a significant improvement in insulin-stimulated glucose disposal: the women's muscles became better at absorbing and using blood sugar after meals. Muscle signalling proteins increased, and NAD+ levels rose in blood. Skeletal muscle showed increased NAD+ metabolite turnover, though steady-state muscle NAD+ content did not significantly change.

This is not a finding about hot flashes or sleep. It is a metabolic finding, and that matters more than it might first appear. Insulin resistance worsens meaningfully at menopause and is a core driver of midsection weight gain, post-meal fatigue, and elevated cardiovascular risk. Improving how cells handle energy is not a trivial benefit. It is closer to the root of several menopause-era problems than the symptom-level treatments most women are offered.

The trial was small (n=25) and selected women with prediabetes. NMN has been tested in postmenopausal women - once, carefully, with a specific and meaningful result.

Two independent randomised trials in older adults found that 250mg of NMN improved sleep quality. A 2022 trial by Kim and colleagues reported improvements in drowsiness measures, largest in participants who took NMN in the afternoon, though an afternoon placebo group showed a similar pattern, suggesting the benefit was primarily driven by a chronobiological timing effect. ⁶ A 2024 trial by Morifuji and colleagues showed improved Pittsburgh Sleep Quality Index scores and maintained walking speed. ⁷ Neither study enrolled menopausal women specifically. Sleep disruption is one of the most commonly reported menopause complaints, and these are the best proxy data currently available.

The most directly relevant human data comes from a 2026 open-label pilot by Holmes and colleagues in 40 women. ² The supplement tested was a closely related NAD+ precursor, NR, combined with pterostilbene. Among women with menopausal symptoms, 75% reported improvement in hot flash frequency and 84% reported improvement in frequency of nights with poor sleep over seven days. The proposed mechanism: increasing NAD+ raises a related molecule called NADPH, which enables an enzyme (17-beta-hydroxysteroid dehydrogenase) to convert estrone - the weaker form of estrogen that dominates after menopause - into estradiol, the more active form. The trial found a significant increase in the estradiol-to-estrone ratio.

This is a small, open-label pilot. Read it as a signal rather than proof. It remains the only human data on NAD+-pathway supplementation and menopausal symptoms, and the mechanism is biologically coherent.

A 2025 meta-analysis pooling 12 NMN trials found no significant effect on fasting glucose, cholesterol, or triglycerides overall. ⁸ NMN's benefits are not universal or guaranteed. The response likely varies by baseline health status, dose, and duration. The Yoshino trial found something meaningful because it selected women whose metabolic function was already impaired.

The Repair is For Youth's NMN product. Each capsule contains 450mg of NMN (as Uthever, an enzymatically produced form), 50mg of apigenin (as ApiAge), and 50mg of pterostilbene. Note that the only placebo-controlled NMN trial in postmenopausal women used 250mg per day - The Repair's dose is higher, though no published RCT has compared dose levels directly.

The only human pilot study on NAD+ supplementation and menopausal symptoms used NR combined with pterostilbene. ² It is worth noting that NMN has not been directly tested for hot flash relief in a clinical trial; NR and NMN are related but distinct NAD+ precursors. The Repair's formula covers the same pterostilbene arm of that mechanism, with NMN as the upstream NAD+ source and apigenin protecting against breakdown.

For readers who want to go deeper on the underlying questions: how NMN differs from raw NAD+ supplementation, how to think about timing your dose, and how much to take given your goals and baseline.

One randomised trial confirms NMN improves metabolic function in postmenopausal women with prediabetes. ¹ The broader NAD+ literature points toward sleep, energy, and cellular repair benefits directly relevant to what menopause disrupts. ^{6 7} The mechanistic case, with estrogen and NAD+ falling together and SIRT1 proposed to link them, is compelling enough to warrant attention rather than dismissal.

The Repair is not a menopause treatment. It is a cellular support strategy that makes particular sense during a life stage when the cellular energy system is under pressure from two directions at once.

For Youth is a science-led longevity brand focused on developing clinically relevant supplements that support healthy ageing and performance at the cellular level. Formulated in collaboration with leading academic researchers, the brand prioritises evidence-based ingredients, advanced delivery technologies, and transparent quality standards.